Shares in pharma giant AstraZeneca (LON:AZN) have dropped £14.40 or 10% today on negative drug trial news. The move has wiped around £30 billion off the company’s stock market valuation in one fell swoop. Missing its endpoint The company said its Wainua heart drug treatment had not met its primary efficacy endpoint in Phase III … Continue reading Why AstraZeneca shares are down 10% today